ASPIRE-Sicklecell Landing Page

Pfizer is pleased to announce the 2016 ASPIRE US Sickle Cell Disease Competitive Research Awards Program

As competition increases for limited research funding, the ASPIRE Sickle Cell Disease program offers a new opportunity for researchers in the United States and underscores Pfizer’s commitment to supporting investigators with an interest in advancing innovation in Sickle Cell Disease.


  • To support basic science, translational and clinical research through a competitive grants program that advances medical knowledge in the pathogenesis and treatment of Sickle Cell Disease.
  • To support innovative pilot studies focused on improving patient outcomes in Sickle Cell Disease.
  • To support academic research as well as the career development of promising young and established scientists.

Areas of Research Focus

Pfizer will consider applications for research projects which address laboratory investigation or clinical research in Sickle Cell Disease. Examples of research topics are listed for guidance; however, other applications will be considered.

Innovative research may be in any of the following areas:
  • Biomarkers of Sickle Cell Disease
  • Phenotypic differences in clinical course and/or response to therapy
  • Clinical trial endpoint validation
  • Patient Reported Outcomes (PRO), Health Related Quality of Life (HRQOL)
  • Improving care of specific complications of Sickle Cell Disease
  • Improving clinical care delivery models
  • Improving acute pain management

Available Awards

The 2016 US Sickle Cell Disease ASPIRE Program is open to US investigators.  Review of applications will be performed by an independent, external panel of experts.  Project duration should be 1 or 2 years, and the approximate total award will be up to $55,000 maximum, inclusive of overhead costs (capped at 28%). 

Applications must be received by Monday, October 17, 2016, 11:59 PM Eastern Daylight Time.